Obesity, kidney dysfunction, and inflammation: interactions in hypertension

JE Hall, AJ Mouton, AA da Silva… - Cardiovascular …, 2021 - academic.oup.com
Abstract Obesity contributes 65–75% of the risk for human primary (essential) hypertension
(HT) which is a major driver of cardiovascular and kidney diseases. Kidney dysfunction …

Device-based therapies for arterial hypertension

L Lauder, M Azizi, AJ Kirtane, M Boehm… - Nature Reviews …, 2020 - nature.com
Arterial hypertension is the most prevalent modifiable risk factor associated with
cardiovascular morbidity and mortality. Although antihypertensive drugs are widely …

Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled …

M Azizi, K Sanghvi, M Saxena, P Gosse, JP Reilly… - The Lancet, 2021 - thelancet.com
Background Endovascular renal denervation reduces blood pressure in patients with mild-to-
moderate hypertension, but its efficacy in patients with true resistant hypertension has not …

Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial

DL Bhatt, M Vaduganathan, DE Kandzari, MB Leon… - The Lancet, 2022 - thelancet.com
Summary Background The SYMPLICITY HTN-3 (Renal Denervation in Patients With
Uncontrolled Hypertension) trial showed the safety but not efficacy of the Symplicity system …

Six-month results of treatment-blinded medication titration for hypertension control after randomization to endovascular ultrasound renal denervation or a sham …

M Azizi, RE Schmieder, F Mahfoud, MA Weber… - Circulation, 2019 - Am Heart Assoc
Background: The multicenter, international, randomized, blinded, sham-controlled
RADIANCE-HTN SOLO trial (A Study of the ReCor Medical Paradise System in Clinical …

Proceedings from the 3rd European Clinical Consensus Conference for clinical trials in device-based hypertension therapies

F Mahfoud, M Azizi, S Ewen, A Pathak… - European heart …, 2020 - academic.oup.com
Proceedings from the 3rd European Clinical Consensus Conference for clinical trials in
device-based hypertension therapies | European Heart Journal | Oxford Academic Skip to Main …

Effects of renal denervation on blood pressures in patients with hypertension: a systematic review and meta-analysis of randomized sham-controlled trials

Y Ogoyama, K Tada, M Abe, S Nanto, H Shibata… - Hypertension …, 2022 - nature.com
The efficacy of renal denervation has been controversial, but recent randomized sham-
controlled trials demonstrated significant blood pressure reductions after renal denervation …

[HTML][HTML] Review and meta-analysis of renal artery damage following percutaneous renal denervation with radiofrequency renal artery ablation

RR Townsend, A Walton, DA Hettrick… - …, 2020 - eurointervention.pcronline.com
Aims: We aimed to estimate the rate of renal artery adverse events following renal
denervation with the most commonly applied radiofrequency catheter system based on a …

12-month results from the unblinded phase of the RADIANCE-HTN SOLO trial of ultrasound renal denervation

M Azizi, J Daemen, MD Lobo, F Mahfoud… - Cardiovascular …, 2020 - jacc.org
Objectives This study reports the 12-month results of the RADIANCE-HTN (A Study of the
ReCor Medical Paradise System in Clinical Hypertension) SOLO trial following unblinding of …

Renal denervation for hypertension: a systematic review and meta-analysis of randomized, blinded, placebo-controlled trials

Y Ahmad, DP Francis, DL Bhatt, JP Howard - Cardiovascular Interventions, 2021 - jacc.org
Objectives The authors performed an updated meta-analysis of randomized placebo-
controlled trials of renal denervation and specifically compared the effect of renal …